...EGFR wild-type, and ALK and ROS1 fusion gene negative 4. ...

We enrolled 24 IIB-IIIC NSCLC patients who did not harbore any EGFR, ALK and ROS-1 driver mutations were treated with Tislelizumab plus chemotherapy...After surgery, pathological response were evaluated and MPR was 37.5%, pCR was 29.2%....Tislelizumab plus chemotherapy were effective in early or locally advanced NSCLC patients as neoadjuvant treatment.

Patients with previously untreated, unresectable, pathologically and radiologically confirmed stage III NSCLC, EGFR/ALK-wild-type, with measurable disease were included. Patients received 3 cycles of carboplatin, paclitaxel (squamous NSCLC) or pemetrexed (non-squamous NSCLC), and tislelizumab, followed by standard thoracic radiotherapy. Patients received consolidation tislelizumab up to 14 additional cycles or until intolerable adverse events....12-months PFS rate was 86.7% (95%CI, 73.8%-99.6%). Objective response rate was 86.7% (95%CI, 73.8%-99.6%), and disease control rate was 96.7% (95%CI, 89.8%-100.0%).

Patients aged ≥ 70 with histologically confirmed locally advanced or metastatic NSCLC, without known sensitizing EGFR mutations or ALK rearrangements were eligible for inclusion….In this updated analysis of our perspective study, TIS plus nab-paclitaxel with or without platinum as first-line treatment for elderly advanced NSCLC patients showed clinical higher ORR, DCR, meaningful PFS benefit and longer DoR, with good safety profile.

In this phase II trial, patients with resectable EGFR wild-type stage IIA to IIIB NSCLC were recruited to receive SBRT (24 Gy in 3 daily fractions) to the primary tumor followed by two cycles of PD-1 inhibitor tislelizumab (200 mg) plus platinum-based doublet chemotherapy (Q3W) before surgical resection....Neoadjuvant SBRT followed by immunochemotherapy yields unprecedently high MPR and pCR rates in NSCLC without EGFR mutation.